Assessment of prolonged proteasome inhibition through ixazomib ‐based oral regimen on newly diagnosed and first‐relapsed multiple myeloma: A real‐world Chinese cohort study

ConclusionIn the real-world Chinese MM population, NDMM and FRMM patients responded favorably to PI-based continuous therapy, demonstrating substantial response rates. The ixazomib-based iCT allows for sustained PI-based treatment, offering promising efficacy and tolerable AEs.

Source: Cancer Medicine - April 30, 2024 Category: Cancer & Oncology Authors: Aijun Liu, Hong Yu, Rui Hou, Zunmin Zhu, Jun ‐ling Zhuang, Li Bao, Zhenling Li, Lihong Liu, Luoming Hua, Yanping Ma, Da Gao, Arong Jin, Xiaohui Suo, Wei Yang, Yuansong Bai, Rong Fu, Deqiang Zheng, Wenming Chen Tags: RESEARCH ARTICLE Source Type: research